The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled “Monoclonal Antibodies: Streamlined Nonclinical Safety Studies.”
Similar Posts
Contra Reumas may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Contra Reumas, a product promoted and sold for joint pain on various websites, including naturistarex.com, and possibly in some retail stores.Laboratory Manual of Quality Policies (ISO 17025 Requirements)
Laboratory Manual of Quality Policies (ISO 17025 Requirements)Alert: NOxBOX Ltd. Issues Correction for NOxBOXi Nitric Oxide Delivery System Due to Rapid Command Input Issue
If a user rapidly presses two or more on-screen buttons, the NOxBOXi Nitric Oxide Delivery System may experience sudden software interruption or restart.Catalent Indiana LLC, Bloomington, IN 483 Issued 07/14/2025
Catalent Indiana LLC, Bloomington, IN 483 Issued 07/14/2025ANDA Assessment Program | GDUFA III Performance Goals and Program Enhancements
GDUFA III includes several enhancements to the ANDA assessment process to maximize the efficiency and utility of each assessment cycle. These enhancements aim to reduce the number of assessment cycles and facilitate timely access to safe, effective, high-quality, and affordable generics.Media Networks Sydney Pty Limited – 687044 – 09/18/2024
Failure to Register and List